Tg Therapeutics (TGTX) Debt to Equity (2011 - 2026)

Tg Therapeutics' Debt to Equity history runs 12 years deep, the most recent figure standing at $1.28 for Q1 2026.

• In Q1 2026, Debt to Equity rose 23.9% year-over-year to $1.28; the TTM figure through Mar 2026 stood at $1.28 (up 23.9% YoY), while the FY2025 annual figure was $0.38, down 65.51% from the prior year.
• Debt to Equity was $1.28 for Q1 2026 at Tg Therapeutics, up from $0.38 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $3.52 in Q1 2023 to a low of $0.38 in Q4 2025.
• Historically, Debt to Equity has averaged $1.03 across 5 years, with a median of $0.71 in 2022.
• The sharpest annual moves came in 2022 and 2024: Debt to Equity surged 1278.44% in 2022, then slumped 82.01% in 2024.
• A 5-year view of Debt to Equity shows it stood at $1.21 in 2022, then tumbled by 48.63% to $0.62 in 2023, then jumped by 76.22% to $1.1 in 2024, then sank by 65.51% to $0.38 in 2025, then jumped by 237.09% to $1.28 in 2026.
• The last three Debt to Equity figures came in at $1.28 (Q1 2026), $0.38 (Q4 2025), and $0.4 (Q3 2025), per Business Quant data.